151383-60-7

Upstream product

• 612-23-7 2-nitrobenzyl chloride 
• 106-47-8 4-chloro-aniline 
• 552-89-6 2-nitro-benzaldehyde 
• 17064-76-5 N-(4-chlorophenyl)-1-(2-nitrophenyl)methanimine 

Downstream Products

• 20887-03-0 N-(2-aminobenzyl)-4-chloroaniline 
• 21141-05-9 3-(4-chlorophenyl)-3,4-dihydroquinazolin-2(1H)-one 
• 728023-77-6 3-(4'-chlorophenyl)-3,4-dihydroquinazoline 
• 873974-10-8 4-chloro-2,6,N-trinitro-N-(2-nitro-benzyl)-aniline 
• 61073-53-8 2-(4-chlorophenyl)-2H-indazole 

Relevant academic research and scientific papers

Integration of Bromine and Cyanogen Bromide Generators for the Continuous-Flow Synthesis of Cyclic Guanidines

A continuous-flow process for the in situ on-demand generation of cyanogen bromide (BrCN) from bromine and potassium cyanide that makes use of membrane-separation technology is described. In order to circumvent the handling, storage, and transportation of elemental bromine, a continuous bromine generator using bromate–bromide synproportionation can optionally be attached upstream. Monitoring and quantification of BrCN generation was enabled through the implementation of in-line FTIR technology. With the Br2 and BrCN generators connected in series, 0.2 mmol BrCN per minute was produced, which corresponds to a 0.8 m solution of BrCN in dichloromethane. The modular Br2/BrCN generator was employed for the synthesis of a diverse set of biologically relevant five- and six-membered cyclic amidines and guanidines. The set-up can either be operated in a fully integrated continuous format or, where reactive crystallization is beneficial, in semi-batch mode.

Synthesis and evaluation of N-analogs of 1,2-diarylethane as Helicobacter pylori urease inhibitors

Therapies based on urease inhibition are now seriously considered as the first line of treatment for infections caused by Helicobacter pylori. However, the present inhibitors are ineffective or unstable in highly acidic gastric juice. Here, we report a series of benzylanilines as effective inhibitors of H. pylori urease. Out of the obtained twenty-one compounds, N-(3,4-dihydroxybenzyl)-4-nitroaniline (4) was evaluated in detail and shows promising features for development as anti-H. pylori agent. Excellent potency against urease in both cell-free extract and intact cell was observed at low concentrations of 4 (IC50 = 0.62 ± 0.04 and 1.92 ± 0.09 μM), which showed over 29- and 54-fold increase in potency with respect to the positive control AHA. The SAR analysis revealed that protection of 3,4-dihydroxy group of 4 as methoxy or changes of 4-NO2 will result in a moderate to dramatic decrease in potency.